791 related articles for article (PubMed ID: 29569427)
21. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
[TBL] [Abstract][Full Text] [Related]
22. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Cha SA; Park YM; Yun JS; Lim TS; Song KH; Yoo KD; Ahn YB; Ko SH
Lipids Health Dis; 2017 Apr; 16(1):58. PubMed ID: 28403877
[TBL] [Abstract][Full Text] [Related]
23. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
[TBL] [Abstract][Full Text] [Related]
24. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
25. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
[TBL] [Abstract][Full Text] [Related]
27. Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
Kim JH; Lyu YS; Kim B; Kim MK; Kim SY; Baek KH; Song KH; Han K; Kwon HS
Diabetes Obes Metab; 2024 Jul; 26(7):2567-2577. PubMed ID: 38644477
[TBL] [Abstract][Full Text] [Related]
28. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
Wang Y; Desai M; Ryan PB; DeFalco FJ; Schuemie MJ; Stang PE; Berlin JA; Yuan Z
Diabetes Res Clin Pract; 2017 Jun; 128():83-90. PubMed ID: 28448895
[TBL] [Abstract][Full Text] [Related]
29. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
30. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
31. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
Filion KB; Lix LM; Yu OH; Dell'Aniello S; Douros A; Shah BR; St-Jean A; Fisher A; Tremblay E; Bugden SC; Alessi-Severini S; Ronksley PE; Hu N; Dormuth CR; Ernst P; Suissa S;
BMJ; 2020 Sep; 370():m3342. PubMed ID: 32967856
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
33. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
34. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Li D; Shi W; Wang T; Tang H
Diabetes Obes Metab; 2018 Aug; 20(8):1972-1976. PubMed ID: 29573110
[TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
36. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
Alkabbani W; Shah BR; Zongo A; Eurich DT; Alsabbagh MW; Gamble JM
Diabetes Obes Metab; 2023 Dec; 25(12):3490-3500. PubMed ID: 37563767
[TBL] [Abstract][Full Text] [Related]
37. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
38. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
[TBL] [Abstract][Full Text] [Related]
39. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
